Reporter brief
A Pilot Randomized Controlled Study of Combinatorial Gerotherapeutics for Healthspan Improvement
What happened
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The study provides no reported findings, so it cannot demonstrate whether metformin or the combination regimens affect healthspan or longevity markers.
- The small sample size (approximately 10 per arm) and short 90-day duration limit generalizability and ability to detect meaningful effects on aging outcomes.
- The combinatorial design confounds individual drug effects, making it impossible to isolate metformin's contribution to any observed outcome.
Study design and sample
Rct; Human.
Up to 30 subjects, demographics not specified
- Design
- Rct
- Sample
- 30
- Journal
- AgelessRx
- Published
- Oct 30, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.